Be the first to like this
Venus Remedies took another step on its R&D journey with its first market authorisation deal with a pharma major in South Africa. The company also launched a key R&D product, Elores, in India, which it expects to become a Rs2bn product in the next 5 yrs. We believe Venus is beginning to show results from its R&D program. With Venus’ intent on monetising its R&D pipeline, there is strong likelihood of continued positive news flow, which should lend buoyancy to the stock price.